Newly Published Research Shows Groundbreaking Joint Treatment Changes the Course of Dog Arthritis Management

Key component in Synovetin OA^® targets inflammation – the source of arthritis – and provides up to one year of pain relief; also enhances potential to prevent further cartilage erosion¹

ATLANTA, July 22, 2025 /PRNewswire/ -- Osteoarthritis (OA) is a painful, progressive and widespread joint disease that affects at least one in four adult dogs – and up to 80% of senior dogs. OA is inflammation in the joint that causes pain, limits mobility and erodes cartilage. Newly published research in Frontiers in Veterinary Science, a leading peer-reviewed journal, highlights a major breakthrough: a treatment that not only relieves osteoarthritis pain at the source but also has the potential to prevent further cartilage erosion. The treatment, Synovetin OA from Exubrion Therapeutics, targets inflammation in the joint directly at the source. Veterinarians have used it to safely and effectively treat thousands of dogs with arthritis.

In preclinical rodent studies, tin-117m (also known as Sn-117m), the key component in Synovetin OA, was proven to have a positive disease-modifying effect due to its direct effect on inflammation.

"Until now, treatments for arthritis in dogs have focused primarily on managing symptoms, without much ability to address the underlying inflammation that causes pain, reduced mobility and disease progression," said Bob Menardi, DVM, Chief Veterinary Officer at Exubrion Therapeutics. "Synovetin OA is a breakthrough in treatment that specifically interrupts the vicious inflammatory cycle¹. This newly-published research in rodents provides hope for slowing the course of the disease."

Targeting Inflammation: The Root of Arthritis in Dogs
Arthritis in dogs is driven by a destructive cycle of inflammation, which causes pain, cartilage breakdown, lameness, limping, limited movement and a poor quality of life. In the newly published research article, "Evidence of Osteoarthritis Disease Modification with a Sn-117m Microparticle Device: A review and validation in mammalian models," researchers examined results from separate studies on rodents and dogs treated with tin-117m, the key component in Synovetin OA. Results showed the following:

• Preclinical research in rats demonstrated a powerful positive disease-modifying effect, showing a 73% reduction in inflammation and a 65% reduction in cartilage degeneration.
  
  
• Clinical trials of dogs with mild to severe arthritis demonstrated up to one year of continued pain relief and joint improvement with no active tin-117m remaining in the joint, providing evidence that further supports an OA disease-focused mechanism of action similar to that seen in rodent models.^1-4,6-8

"This review substantiates [Sn-117m] as a transformative veterinary therapy, bridging preclinical insights with clinical outcomes that strongly support a positive disease-modifying mechanism," the authors of Frontiers Veterinary Science abstract conclude¹. The complete research can be found here.

What Makes Synovetin OA Different
Synovetin OA provides up to one full year of pain relief with just one fast, easy treatment. It is injected directly into the affected joint during an outpatient visit and leverages the power of tin-117m, a highly advanced medical radiotherapy, to specifically target and destroy harmful cells responsible for painful inflammation, addressing the cause of the disease and not just masking symptoms. The treatment works locally, targeting only the inflamed joint lining, so it doesn't affect the rest of the body. In thousands of dogs treated since 2021, veterinarians have reported no systemic side effects.

Synovetin OA is available at treatment centers across the U.S. To learn more or to find the nearest treating veterinarian, visit ActiveDogNow.com.

About Exubrion Therapeutics
Exubrion Therapeutics is an animal health company focused on relieving animal arthritis pain and improving the quality of life with Synovetin OA^®, a groundbreaking radiotherapeutic treatment for osteoarthritis that harnesses the power of tin-117m. Our mission is to ensure veterinarians and pet parents have an effective, safe and long-lasting option that targets the pain and progression of osteoarthritis.

References:

1. Bendele A, Doerr CA, Gonzales GR, et al. Evidence of osteoarthritis disease modification with a Sn-117m microparticle device: a review and validation in mammalian models. Front. Vet. Sci. 2-25;12:1-13 doi: 10.3389/fvets.2025.1621296.
2. Aulakh KS, Lopez MJ, Hudson C, et al. Prospective Clinical Evaluation of Intra-Articular Injection of Tin-117m (^117mSn) Radiosynoviorthesis Agent for Management of Naturally Occurring Elbow Osteoarthritis in Dogs: A Pilot Study. Vet Med (Auckl). 2021. Jun 4;12:117-128. doi: 10.2147/VMRR.S295309. PMID: 34113552; PMCID: PMC8187093.
3. Donecker J, Fabiani M, Gaschen L, Aulakh KS. Treatment response in dogs with naturally occurring grade 3 elbow osteoarthritis following intra-articular injection of 117mSn (tin) colloid. PLoS One. 2021. Jul 19;16(7):e0254613. doi: 10.1371/journal.pone.0254613. PMID: 34280212; PMCID: PMC8289027.
4. Donecker J, Lattimer JC, Gaschen L, Aulakh KS. Safety and Clinical Response Following a Repeat Intraarticular Injection of Tin-117m (^117mSn) Colloid in Dogs with Elbow Osteoarthritis. Vet Med (Auckl). 2021. Dec 17;12:325-335. doi: 10.2147/VMRR.S345144. PMID: 34950571; PMCID: PMC8691448.
5. Lattimer JC, Selting KA, Lunceford JM, et al. Intraarticular injection of a tin-117m radiosynoviorthesis agent in normal canine elbows causes no adverse effects. Vet Radiol Ultrasound. 2019. Sep;60(5):567-574. doi: 10.1111/vru.12757. Epub 2019 Jun 2. PMID: 31155782.
6. Doerr, CA, Bendele, A, Simon, J, Stevenson, N, and Gonzales, G. Validation of the use of homogeneous Sn-117m colloid radiosynoviorthesis in a GLP osteoarthritis rat model. J Nucl Med. (2016) 57:323
7. Doerr C, et al. Poster presented at the Society of Nuclear Medicine & Molecular Imaging Annual Conference. San Diego, CA. 2016.
8. Data on File. Pathology Report. Bolder BioPATH, Inc.; Boulder, CO.

SOURCE Synovetin OA